Strain Data Sheet



BRC No.RBRC01869
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameB6.129-Nod2<tm1Jhgt>
Former Common nameCard15 KO (C57BL/6N background)
H-2 Haplotype
ES Cell line
Background strain
Strain developmentDeveloped by Marco Giovannini, INSERM. PGK-hygromycin cassette was removed by cre recombinase.
Strain descriptionThis mouse was produced from the knock-in targeting of Card15 (Nod2) locus with EGFP cassette. The expression of the GFP is relatively low. C57BL/6 congenic (RBRC01869), C57BL/6 and 129 mixed background (RBRC01941).
Colony maintenanceHomozygote x Homozygote
ReferencesPLoS One, 2(6), e523 (2007). 17565376

Health Report

Examination Date / Room / Rack


Gene info
Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter
Nod2caspase recruitment domain family, member 158Nod2F830032C23Rik, IBD1, Nod2

Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter
EGFPEnhanced Green Fluorescent Protein (Aequorea victoria)8EGFP

Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter
loxPphage P1 loxP8loxP


Donor DNAjellyfish EGFP cDNA, SV40 polyA, Phage P1 loxP site, mouse Nod2 genomic DNA
Research applicationCre/loxP system
Fluorescent Proteins/lacZ System
Immunology and Inflammation Research
Internal/Organ Research
Mouse Models for Human Disease
Specific Term and ConditionsIn publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
DepositorMarco Giovannini (INSERM)
Strain Statusan icon for Frozen embryosFrozen embryos
Strain AvailabilityRecovered litters from cryopreserved embryos (2 to 4 months)
Cryopreserved embryos (within 1 month)
Additional Info.Mouse of the Month Jun 2007
Necessary documents for ordering:
  1. Order form (Japanese / English)
  2. Category I MTA: MTA for distribution with RIKEN BRC (Japanese / English)
  3. Acceptance of responsibility for living modified organism (Japanese / English)

Genotyping protocol -PCR-

BRC mice in Publications

Zong J, Salim M, Zhou H, Bian ZY, Dai J, Yuan Y, Deng W, Zhang JY, Zhang R, Wu QQ, Tang QZ.
NOD2 deletion promotes cardiac hypertrophy and fibrosis induced by pressure overload.
Lab Invest 93(10) 1128-36(2013) 23958879